Allogene Therapeutics, Inc. Operating Expenses
Allogene Therapeutics, Inc. (ALLO) reported Operating Expenses of $51.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Allogene Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $51.56M, a 9.26% decline year-over-year.
- Allogene Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $46.09M, a 29.30% decline year-over-year.
- Allogene Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $42.40M, a 29.90% decline year-over-year.
- Allogene Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $44.90M, a 37.44% decline year-over-year.
- Allogene Therapeutics, Inc. operating expenses for fiscal 2025 was $209.31M, a 23.39% decline from fiscal 2024.
- Allogene Therapeutics, Inc. operating expenses for fiscal 2024 was $273.22M, a 16.66% decline from fiscal 2023.
- Allogene Therapeutics, Inc. operating expenses for fiscal 2023 was $327.83M, a 2.34% decline from fiscal 2022.
- Allogene Therapeutics, Inc. operating expenses for fiscal 2022 was $335.69M, a 14.07% increase from fiscal 2021.
| Period end | Operating Expenses 1 month | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $51.56M 10-Q · filed 2026-08-12 | $97.65M 10-Q · filed 2026-08-12 | $140.06M derived: sum of 3 quarters · filed 2026-08-12 | $184.96M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $46.09M 10-Q · filed 2026-05-13 | $88.50M derived: sum of 2 quarters · filed 2026-05-13 | $133.40M derived: sum of 3 quarters · filed 2026-05-13 | $190.22M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $42.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $87.31M derived: sum of 2 quarters · filed 2026-03-12 | $144.12M derived: sum of 3 quarters · filed 2026-08-12 | $209.31M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $44.90M 10-Q · filed 2025-11-06 | $101.72M derived: sum of 2 quarters · filed 2026-08-12 | $166.91M 10-Q · filed 2025-11-06 | $227.40M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $56.82M 10-Q · filed 2026-08-12 | $122.01M 10-Q · filed 2026-08-12 | $182.50M derived: sum of 3 quarters · filed 2026-08-12 | $254.27M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $65.19M 10-Q · filed 2026-05-13 | $125.68M derived: sum of 2 quarters · filed 2026-05-13 | $197.46M derived: sum of 3 quarters · filed 2026-05-13 | $268.89M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $60.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $132.26M derived: sum of 2 quarters · filed 2026-03-12 | $203.69M derived: sum of 3 quarters · filed 2026-03-12 | $273.22M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $71.77M 10-Q · filed 2025-11-06 | $143.21M derived: sum of 2 quarters · filed 2025-11-06 | $212.73M 10-Q · filed 2025-11-06 | $297.86M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $71.43M 10-Q · filed 2025-08-13 | $140.96M 10-Q · filed 2025-08-13 | $226.09M derived: sum of 3 quarters · filed 2025-08-13 | $289.11M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $69.53M 10-Q · filed 2025-05-13 | $154.66M derived: sum of 2 quarters · filed 2025-05-13 | $217.67M derived: sum of 3 quarters · filed 2025-05-13 | $298.24M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $85.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $148.15M derived: sum of 2 quarters · filed 2025-03-13 | $228.71M derived: sum of 3 quarters · filed 2025-03-13 | $327.83M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $63.02M 10-Q · filed 2024-11-07 | $143.58M derived: sum of 2 quarters · filed 2024-11-07 | $242.70M 10-Q · filed 2024-11-07 | $339.12M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $80.56M 10-Q · filed 2024-08-07 | $179.68M 10-Q · filed 2024-08-07 | $276.11M derived: sum of 3 quarters · filed 2024-08-07 | $358.64M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $99.12M 10-Q · filed 2024-05-13 | $195.54M derived: sum of 2 quarters · filed 2024-05-13 | $278.08M derived: sum of 3 quarters · filed 2024-05-13 | $354.76M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $96.42M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | $178.96M derived: sum of 2 quarters · filed 2024-03-14 | $255.64M derived: sum of 3 quarters · filed 2024-03-14 | $335.69M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $82.54M 10-K · filed 2024-03-14 | $159.22M derived: sum of 2 quarters · filed 2024-03-14 | $239.27M 10-K · filed 2024-03-14 | $313.21M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $76.68M 10-K · filed 2024-03-14 | $156.73M 10-K · filed 2024-03-14 | $230.68M derived: sum of 3 quarters · filed 2024-03-14 | $308.40M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $80.05M 10-K · filed 2024-03-14 | $154.00M derived: sum of 2 quarters · filed 2024-03-14 | $231.72M derived: sum of 3 quarters · filed 2024-03-14 | $302.79M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $73.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $151.66M derived: sum of 2 quarters · filed 2024-03-14 | $222.74M derived: sum of 3 quarters · filed 2024-03-14 | $294.28M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $77.72M 10-Q · filed 2022-11-02 | $148.79M derived: sum of 2 quarters · filed 2022-11-02 | $220.34M 10-Q · filed 2022-11-02 | $289.70M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $71.07M 10-Q · filed 2022-08-09 | $142.62M 10-Q · filed 2022-08-09 | $211.98M derived: sum of 3 quarters · filed 2024-03-14 | $280.02M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $71.55M 10-Q · filed 2022-05-04 | $140.91M derived: sum of 2 quarters · filed 2024-03-14 | $208.95M derived: sum of 3 quarters · filed 2024-03-14 | $272.11M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $69.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $137.40M derived: sum of 2 quarters · filed 2024-03-14 | $200.56M derived: sum of 3 quarters · filed 2024-03-14 | $258.24M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $68.04M 10-Q · filed 2021-11-04 | $131.20M derived: sum of 2 quarters · filed 2021-11-04 | $188.88M 10-Q · filed 2021-11-04 | $253.46M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $63.16M 10-Q · filed 2021-08-04 | $120.84M 10-Q · filed 2021-08-04 | $185.42M derived: sum of 3 quarters · filed 2022-02-23 | $240.43M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $57.68M 10-Q · filed 2021-05-05 | $122.26M derived: sum of 2 quarters · filed 2022-02-23 | $177.27M derived: sum of 3 quarters · filed 2022-02-23 | $223.23M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $64.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $119.59M derived: sum of 2 quarters · filed 2022-02-23 | $165.55M derived: sum of 3 quarters · filed 2022-02-23 | $202.01M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $55.01M 10-Q · filed 2020-11-04 | $100.97M derived: sum of 2 quarters · filed 2020-11-04 | $137.43M 10-Q · filed 2020-11-04 | $170.48M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $45.96M 10-Q · filed 2020-08-05 | $82.42M 10-Q · filed 2020-08-05 | $115.47M derived: sum of 3 quarters · filed 2021-02-25 | $137.66M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $36.46M 10-Q · filed 2020-05-06 | $69.51M derived: sum of 2 quarters · filed 2021-02-25 | $91.69M derived: sum of 3 quarters · filed 2021-02-25 | $226.71M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $33.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $55.23M derived: sum of 2 quarters · filed 2021-02-25 | $190.25M derived: sum of 3 quarters · filed 2021-02-25 | $192.84M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $22.19M 10-Q · filed 2019-11-05 | $157.20M derived: sum of 2 quarters · filed 2019-11-05 | $159.80M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $135.01M 10-Q · filed 2019-08-07 | $137.61M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $2.60M 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $2.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |